Search - tctmd.com

Displaying 101 - 120 of 830

Sort: Relevancy | Date

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

L.A. McKeown

April 11, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

Presentation ACC 2024

Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration

Presenter: Steven E. Nissen

April 08, 2024

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

Presentation ACC 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presenter: Michael J. Koren

April 06, 2024

News Conference News ACC 2024

Faster CAC Progression After Menopause May Warrant Intensified Therapy

L.A. McKeown

April 04, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News

Lifestyle Changes Can Curb CVD Risk After Adverse Pregnancy Outcomes

Yael L. Maxwell

March 26, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Conference News

Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality

Michael O'Riordan

March 22, 2024

News Opinion CV Team Dispatch

March 2024 Dispatch for the CV Team

L.A. McKeown

March 01, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

News Daily News

High-Protein Diets Linked to Amino Acid Activation of ASCVD Pathway

L.A. McKeown

February 21, 2024

News Daily News

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

Yael L. Maxwell

February 15, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

Advertisement

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

Need a Statin for Primary Prevention? There’s an App for That

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Faster CAC Progression After Menopause May Warrant Intensified Therapy

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Lifestyle Changes Can Curb CVD Risk After Adverse Pregnancy Outcomes

Bempedoic Acid Gains CV Risk Reduction Indication

Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality

March 2024 Dispatch for the CV Team

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

High-Protein Diets Linked to Amino Acid Activation of ASCVD Pathway

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content